Tufa Tesfaye H, Prager Sarah, Lavelanet Antonella F, Kim Caron
Department of Obstetrics and Gynecology, Saint Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia.
UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), Department of Sexual and Reproductive Health and Research, World Health Organization, Geneva, Switzerland.
Contracept X. 2020 Nov 9;2:100046. doi: 10.1016/j.conx.2020.100046. eCollection 2020.
Clinicians have used feticidal agents prior to second trimester abortion for many years. Despite the widespread use of various agents to induce fetal demise, a comprehensive or systematic review of the evidence is lacking on the safety, effectiveness, and most effective routes of administration.
To evaluate the existing drugs and routes of administration used in inducing fetal demise prior to abortion, and to determine the safety, effectiveness, and acceptability of these feticidal agents.
We searched PubMed, EMBASE, CINAHL, POPLINE, and Global Index Medicus to identify studies describing pharmacologic agents used to induce fetal demise prior to termination of pregnancy. We included randomized controlled trials and observational studies comparing digoxin, potassium chloride (KCL), and lidocaine to induce fetal demise. We included studies that evaluated the primary outcomes of safety and effectiveness, including success in achieving fetal demise, induction to expulsion time for medical abortion, dilation and evacuation time, as well as maternal side effects and complications. Two authors independently screened abstracts and full texts. One reviewer extracted data from the included studies, which was counterchecked by a second reviewer.
We identified eight studies that met inclusion criteria: three randomized controlled trials, and five observational studies. A total of 4505 women received drugs to induce fetal demise at 17 to 38 weeks' gestation, including digoxin ( = 4174), KCL ( = 324), and lidocaine ( = 7). Intra-fetal digoxin was superior to intra-amniotic digoxin in achieving fetal demise (OR 3.51, 95% CI 1.60, 7.78). Intracardiac KCL 15% 2-3 mL reduced induction to expulsion time by 320 min (p <.006).Similarly, intracardiac KCL 15% 1-3 ml reduced dilation and evacuation time from 16.1 ± 7.9 min to 12.7 ± 5 min (p < 0.001). Intracardiac lidocaine 2% 10 mL was more effective at achieving fetal demise than intracardiac KCL 6 mmol (85.7% vs. 57.9%). Intra-amniotic and intra-fetal digoxin 1 mg, as compared to no feticidal agent, led to greater pre-procedure expulsion, hospital readmission, and the presence of one or more signs of infection.
Evidence from included cohort studies demonstrates that digoxin, KCL, and lidocaine are all effective in inducing fetal demise. Intra-fetal administration of digoxin is superior to intra-amniotic digoxin administration. Administration of feticide using intracardiac KCL may shorten the abortion experience. Limited data from observational studies also supports an increase in maternal side effects and/or complications related to the administration of digoxin.
Intra-fetal administration of digoxin is more effective in achieving fetal demise when compared to intra-amniotic administration. There is a knowledge gap in determining the single best drug for inducing fetal demise prior to abortion. Additional research is needed to compare different feticidal agents in terms of safety and effectiveness.
多年来,临床医生在孕中期流产前一直使用杀胎药物。尽管广泛使用各种药物来诱导胎儿死亡,但缺乏关于安全性、有效性和最有效给药途径的全面或系统的证据综述。
评估流产前用于诱导胎儿死亡的现有药物和给药途径,并确定这些杀胎药物的安全性、有效性和可接受性。
我们检索了PubMed、EMBASE、CINAHL、POPLINE和Global Index Medicus,以识别描述在终止妊娠前用于诱导胎儿死亡的药物的研究。我们纳入了比较地高辛、氯化钾(KCL)和利多卡因诱导胎儿死亡的随机对照试验和观察性研究。我们纳入了评估安全性和有效性主要结果的研究,包括成功实现胎儿死亡、药物流产从引产到排出的时间、扩张和清宫时间,以及母体副作用和并发症。两位作者独立筛选摘要和全文。一位审阅者从纳入的研究中提取数据,由另一位审阅者进行核对。
我们确定了八项符合纳入标准的研究:三项随机对照试验和五项观察性研究。共有4505名妇女在妊娠17至38周时接受了诱导胎儿死亡的药物,包括地高辛(n = 4174)、KCL(n = 324)和利多卡因(n = 7)。胎儿内注射地高辛在实现胎儿死亡方面优于羊膜腔内注射地高辛(OR 3.51,95% CI 1.60,7.78)。心内注射15% KCL 2 - 3 mL可使引产到排出时间缩短320分钟(p <.006)。同样,心内注射15% KCL 1 - 3 mL可使扩张和清宫时间从16.1 ± 7.9分钟缩短至12.7 ± 5分钟(p < 0.001)。心内注射2%利多卡因10 mL在实现胎儿死亡方面比心内注射6 mmol KCL更有效(85.7%对57.9%)。与不使用杀胎药物相比,羊膜腔内和胎儿内注射1 mg地高辛导致术前排出、再次入院以及出现一种或多种感染迹象的情况更多。
纳入的队列研究证据表明,地高辛、KCL和利多卡因在诱导胎儿死亡方面均有效。胎儿内注射地高辛优于羊膜腔内注射地高辛。使用心内注射KCL进行杀胎给药可能会缩短流产过程。观察性研究的有限数据也支持与地高辛给药相关的母体副作用和/或并发症有所增加。
与羊膜腔内注射相比,胎儿内注射地高辛在实现胎儿死亡方面更有效。在确定流产前诱导胎儿死亡的单一最佳药物方面存在知识空白。需要进一步研究来比较不同杀胎药物在安全性和有效性方面的差异。